Premium
Treating paediatric community‐acquired pneumonia in the era of antimicrobial resistance
Author(s) -
Galli L,
Montagnani C,
Chiappini E,
Martino M
Publication year - 2013
Publication title -
acta paediatrica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.772
H-Index - 115
eISSN - 1651-2227
pISSN - 0803-5253
DOI - 10.1111/apa.12503
Subject(s) - medicine , antimicrobial , antibiotic resistance , pneumonia , intensive care medicine , epidemiology , drug resistance , antibiotics , antimicrobial drug , community acquired pneumonia , microbiology and biotechnology , biology
Increasing levels of paediatric community‐acquired pneumonia ( CAP ), caused by drug‐resistant bacteria and antimicrobial resistance, vary with age and countries and, in some cases, serotypes. When empirical first‐line treatment administration fails, paediatricians should consider second‐line treatments based on the prevalence of local resistance. A more judicious use of antimicrobial agents is also required. Conclusion Knowledge of local epidemiology and an appropriate use of antimicrobial drugs are necessary to treat CAP in this era of antimicrobial resistance.